e-ISSN 2329-0072

Logo

Medical
MSM  BR

AmJCaseRep

In-stent restenosis treatment – our own experience Part III. Clinical manifestation of in-stent restenosis after bare metal stent implantation

Beata Mikulska, Krzysztof Chiżyński

Med Sci Tech 2009; 50(1): RA19-22

ID: 881657

Available online:

Published: 2009-03-22


Introduction: The purpose of this study was to evaluate the clinical manifestation of in-stent restenosis (ISR) after bare metal stent (BMS) implantation. Materials and methods: The examination comprised 98 consecutive patients with in-stent restenosis (ISR). The study group consists of 59 patients, aged 37-87 (mean age 60.6) with ISR after BMS implantation treated with the aid of drug eluting stent (DES) implantation and the control group consists of 39 patients, aged 40-80 (mean age 60) with ISR after BMS implantation treated with plain old balloon angioplasty (POBA). Clinical manifestation of ISR in BMS and time since BMS implantation to angiographically revealed restenosis were analyzed. Results: In our study, the most frequent form of ISR manifestation was acute coronary syndrome (ACS) (62.7% of patients in the study group and 74.3% of patients in the control group; NS) which was manifested during first six months after stent implantation. The increase of troponin T was not observed in most cases in these acute coronary syndromes (ACS), so unstable coronary disease (UA) was the most often ISR manifestation and it was recognized with the frequency of 47.4% of patients in the study group and in 38.5% of patients in the control group; NS). Conclusions: 1. In majority of patients the first manifestation of in-stent restenosis was acute coronary syndrome. 2. It was mainly troponin negative acute coronary syndrome. 3. The most often time of in-stent restenosis manifestation was the first six months after stent implantation. (Clin Exp Med Lett 2009; 50(1)19-22)

Keywords: in-stent restenosis, bare metal stent, clinical manifestation of in-stent restenosis, acute coronary syndrome



Back